(Total Views: 607)
Posted On: 11/09/2021 11:29:32 AM
Post# of 153903
bottom line leronlimab is a massive threat to gilead and their trodelvy investment
"Gilead Sciences has turned blockbuster contender Trodelvy’s conditional FDA nod in triple-negative breast cancer into a full and better one, taking another step toward making the $21 billion it shelled out for the drug’s developer, Immunomedics, financially worthwhile."
"Gilead Sciences has won full FDA approval for Trodelvy in triple-negative breast cancer after at least two prior therapies. (Olivier Le Moal/Getty Images)"
"Gilead Sciences has turned blockbuster contender Trodelvy’s conditional FDA nod in triple-negative breast cancer into a full and better one, taking another step toward making the $21 billion it shelled out for the drug’s developer, Immunomedics, financially worthwhile."
"Gilead Sciences has won full FDA approval for Trodelvy in triple-negative breast cancer after at least two prior therapies. (Olivier Le Moal/Getty Images)"
(3)
(0)
